-
1
-
-
10744223657
-
In vitro activity of TD-6424 against Staphylococcus aureus
-
Pace JL, Krause K, Johnston D, et al. In vitro activity of TD-6424 against Staphylococcus aureus. Antimicrob Agents Chemother 2003;47:3602-4.
-
(2003)
Antimicrob Agents Chemother
, vol.47
, pp. 3602-3604
-
-
Pace, J.L.1
Krause, K.2
Johnston, D.3
-
2
-
-
3042658714
-
Hydrophobic vancomycin derivatives with improved ADME properties: Discovery of telavancin (TD-6424)
-
Leadbetter MR, Adams SM, Bazzini B, et al. Hydrophobic vancomycin derivatives with improved ADME properties: discovery of telavancin (TD-6424). J Antibiot (Tokyo) 2004;57:326-36.
-
(2004)
J Antibiot (Tokyo)
, vol.57
, pp. 326-336
-
-
Leadbetter, M.R.1
Adams, S.M.2
Bazzini, B.3
-
3
-
-
33845365227
-
Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus
-
Barcia-Macay M, Lemaire S, Mingeot-Leclercq MP, Tulkens PM, Van Bambeke F. Evaluation of the extracellular and intracellular activities (human THP-1 macrophages) of telavancin versus vancomycin against methicillin-susceptible, methicillin-resistant, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus. J Antimicrob Chemother 2006;58:1177-84.
-
(2006)
J Antimicrob Chemother
, vol.58
, pp. 1177-1184
-
-
Barcia-Macay, M.1
Lemaire, S.2
Mingeot-Leclercq, M.P.3
Tulkens, P.M.4
Van Bambeke, F.5
-
4
-
-
33748089329
-
Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus
-
Leuthner KD, Cheung CM, Rybak MJ. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus. J Antimicrob Chemother 2006;58:338-43.
-
(2006)
J Antimicrob Chemother
, vol.58
, pp. 338-343
-
-
Leuthner, K.D.1
Cheung, C.M.2
Rybak, M.J.3
-
5
-
-
35948988437
-
In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe
-
Jansen WT, Verel A, Verhoef J, Milatovic D. In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe. Antimicrob Agents Chemother 2007;51:3420-4.
-
(2007)
Antimicrob Agents Chemother
, vol.51
, pp. 3420-3424
-
-
Jansen, W.T.1
Verel, A.2
Verhoef, J.3
Milatovic, D.4
-
6
-
-
2442674119
-
Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentrationdependent anti-infective with multiple mechanisms of action against gram-positive bacteria
-
King A, Phillips I, Kaniga K. Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentrationdependent anti-infective with multiple mechanisms of action against gram-positive bacteria. J Antimicrob Chemother 2004;53:797-803.
-
(2004)
J Antimicrob Chemother
, vol.53
, pp. 797-803
-
-
King, A.1
Phillips, I.2
Kaniga, K.3
-
7
-
-
2542485522
-
In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic grampositive species and Corynebacterium spp
-
Goldstein EJ, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez HT. In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic grampositive species and Corynebacterium spp. Antimicrob Agents Chemother 2004;48:2149-52.
-
(2004)
Antimicrob Agents Chemother
, vol.48
, pp. 2149-2152
-
-
Goldstein, E.J.1
Citron, D.M.2
Merriam, C.V.3
Warren, Y.A.4
Tyrrell, K.L.5
Fernandez, H.T.6
-
8
-
-
20044363986
-
Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus
-
Higgins DL, Chang R, Debabov DV, et al. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2005;49:1127-34.
-
(2005)
Antimicrob Agents Chemother
, vol.49
, pp. 1127-1134
-
-
Higgins, D.L.1
Chang, R.2
Debabov, D.V.3
-
9
-
-
21144449191
-
Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria
-
Stryjewski ME, O'Riordan WD, Lau WK, et al. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin Infect Dis 2005;40:1601-7.
-
(2005)
Clin Infect Dis
, vol.40
, pp. 1601-1607
-
-
Stryjewski, M.E.1
O'Riordan, W.D.2
Lau, W.K.3
-
10
-
-
33644637932
-
Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study
-
Stryjewski ME, Chu VH, O'Riordan WD, et al. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother 2006;50:862-7.
-
(2006)
Antimicrob Agents Chemother
, vol.50
, pp. 862-867
-
-
Stryjewski, M.E.1
Chu, V.H.2
O'Riordan, W.D.3
-
11
-
-
67049094129
-
Telavancin for hospital-acquired pneumonia, including ventilator-associated pneumonia: The ATTAIN studies [abstract]
-
Rubinstein E, Corey GR, Stryjewski ME, et al. Telavancin for hospital-acquired pneumonia, including ventilator-associated pneumonia: the ATTAIN studies [abstract]. Clin Microbiol Infect 2008;14(suppl 7):S14.
-
(2008)
Clin Microbiol Infect
, vol.14
, Issue.SUPPL. 7
-
-
Rubinstein, E.1
Corey, G.R.2
Stryjewski, M.E.3
-
12
-
-
43949095864
-
Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms
-
Stryjewski ME, Graham DR, Wilson SE, et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis 2008;46:1683-93.
-
(2008)
Clin Infect Dis
, vol.46
, pp. 1683-1693
-
-
Stryjewski, M.E.1
Graham, D.R.2
Wilson, S.E.3
-
13
-
-
11244316714
-
Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects
-
Shaw JP, Seroogy J, Kaniga K, Higgins DL, Kitt M, Barriere S. Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob Agents Chemother 2005;49:195-201.
-
(2005)
Antimicrob Agents Chemother
, vol.49
, pp. 195-201
-
-
Shaw, J.P.1
Seroogy, J.2
Kaniga, K.3
Higgins, D.L.4
Kitt, M.5
Barriere, S.6
-
14
-
-
0003979206
-
-
Theravance, Inc, South San Francisco, CA;
-
Theravance, Inc. Data on file. South San Francisco, CA; 2006.
-
(2006)
Data on file
-
-
-
15
-
-
10744232330
-
The conduct of in vitro and in vivo drug-drug interaction studies: A Pharmaceutical Research and Manufacturers of America (PhRMA) perspective
-
Bjornsson TD, Callaghan JT, Einolf HJ, et al. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 2003;31:815-32.
-
(2003)
Drug Metab Dispos
, vol.31
, pp. 815-832
-
-
Bjornsson, T.D.1
Callaghan, J.T.2
Einolf, H.J.3
-
16
-
-
0034807892
-
Optimizing drug development: Strategies to assess drug metabolism/transporter interaction potential - toward a consensus
-
Tucker GT, Houston JB, Huang SM. Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential - toward a consensus. Pharm Res 2001;18:1071-80.
-
(2001)
Pharm Res
, vol.18
, pp. 1071-1080
-
-
Tucker, G.T.1
Houston, J.B.2
Huang, S.M.3
-
17
-
-
77952585757
-
-
Rockville, MD: U.S. Food and Drug Administration;, Available from, Accessed March 26, 2009
-
Center for Drug Evaluation and Research. Drug development and drug interactions: table of substrates, inhibitors and inducers. Rockville, MD: U.S. Food and Drug Administration; 2006. Available from http://www.fda.gov/Drugs/ DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ ucm093664.htm. Accessed March 26, 2009.
-
(2006)
Drug development and drug interactions: Table of substrates, inhibitors and inducers
-
-
-
18
-
-
75849155094
-
-
Guidance for industry. Bioavailability and bioequivalence studies for orally administered drug products, general considerations. Rockville, MD:, Available from, Accessed March 26
-
Center for Drug Evaluation and Research. Guidance for industry. Bioavailability and bioequivalence studies for orally administered drug products - general considerations. Rockville, MD: U.S. Food and Drug Administration; 2003. Available from http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm070124.pdf. Accessed March 26, 2009.
-
(2003)
-
-
-
19
-
-
27144556111
-
Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients
-
Lepper ER, Baker SD, Permenter M, et al. Effect of common CYP3A4 and CYP3A5 variants on the pharmacokinetics of the cytochrome P450 3A phenotyping probe midazolam in cancer patients. Clin Cancer Res 2005;11:7398-404.
-
(2005)
Clin Cancer Res
, vol.11
, pp. 7398-7404
-
-
Lepper, E.R.1
Baker, S.D.2
Permenter, M.3
|